FIELD: medicine.
SUBSTANCE: invention refers to medicine and aims at treating a patient diagnosed with previously treated triple-negative metastatic breast cancer. What is presented is a method according to which the patient receives a treatment regimen combining chemotherapy with administering an effective amount of anti-VEGF antibodies, wherein the treatment regimen with chemotherapy comprises administering at least one chemotherapeutic agent specified in a group consisting of taxanes, capecitabine, gemcitabine and vinorelbine.
EFFECT: invention provides a higher survival rate with no disease progression by treating the individual with the anti-VEGF antibody, in particular bevacizumab in a combination with the chemotherapy.
7 cl, 4 dwg, 7 tbl 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTI-ANGIOGENESIS THERAPY USED FOR TREATING BREAST CANCER | 2009 |
|
RU2531948C2 |
| COMBINED THERAPY FOR TREATING GLIOBLASTOMA | 2014 |
|
RU2692075C2 |
| TREATMENT WITH ANTIBODIES AGAINST VEGF | 2004 |
|
RU2519669C2 |
| COMPOSITIONS AND METHODS OF TREATING AND DIAGNOSING CANCER-RESISTANT CANCER | 2015 |
|
RU2710735C2 |
| ANTIBODIES AGAINST PD-1 FOR TREATMENT OF LUNG CANCER | 2018 |
|
RU2771759C2 |
| DIAGNOSTIC METHODS AND COMPOSITIONS FOR TREATING GLIOBLASTOMA | 2014 |
|
RU2706968C2 |
| METHODS OF DIAGNOSIS AND COMPOSITION FOR CANCER TREATMENT | 2013 |
|
RU2666627C2 |
| BIOLOGICAL MARKERS FOR IDENTIFYING PATIENTS FOR TREATMENT WITH VEGF ANTAGONISTS | 2013 |
|
RU2659173C2 |
| INHIBITION OF DISSEMINATION OF TUMOUR USING Bv8 OR G-CSF ANTAGONISTS | 2010 |
|
RU2567803C2 |
| COMBINED THERAPY WITH USING ALPHA5BETA1 ANTAGONISTS | 2007 |
|
RU2465282C2 |
